Cybin(CYBN) - 2021 Q4 - Annual Report

® Cybin Announces Initiation of Kernel Flow Feasibility Study Measuring Psychedelic Effects on the Brain TORONTO, CANADA – March 31, 2022 – Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (Cybin or the Company), a biopharmaceutical company focused on progressing "Psychedelics to Therapeutics ", today announced that the first study visit has been conducted in a Cybin-sponsored feasibility study evaluating Kernel's quantitative neuroimaging technology, Flow, to measure ketamine's psychedelic effects on cerebral co ...